Fallon Renee M, Girotto Jennifer E
Maine Medical Center, Department of Pharmacy Services, Portland, Maine.
J Pediatr Pharmacol Ther. 2008 Jul;13(3):124-40. doi: 10.5863/1551-6776-13.3.124.
Fungal infections are a significant cause of morbidity and mortality in immunocompromised children. Since the beginning of the 21st century, many new antifungals including the echinocandins (i.e., caspofungin, micafungin, anidulafungin) and the newer generation triazoles (i.e., voriconazole and posaconazole) have received Food and Drug Administration approval. Unfortunately, despite making great strides in the adult arena, these agents are not currently approved in the pediatric population. However, pharmacokinetic data and clinical experiences with these agents in infants, children, and adolescents are mounting. As such, this review will discuss key concepts in pediatric pharmacology and clinical use of these newer antifungal agents.
真菌感染是免疫功能低下儿童发病和死亡的重要原因。自21世纪初以来，许多新型抗真菌药物，包括棘白菌素类（即卡泊芬净、米卡芬净、阿尼芬净）和新一代三唑类（即伏立康唑和泊沙康唑）已获得美国食品药品监督管理局的批准。不幸的是，尽管在成人领域取得了很大进展，但这些药物目前尚未在儿科人群中获得批准。然而，关于这些药物在婴儿、儿童和青少年中的药代动力学数据和临床经验正在不断积累。因此，本综述将讨论这些新型抗真菌药物在儿科药理学和临床应用中的关键概念。
